Zymeworks Inc. (NASDAQ:ZYME – Free Report) – HC Wainwright lowered their Q3 2026 earnings estimates for Zymeworks in a research note issued on Wednesday, August 5th. HC Wainwright has a “Buy” rating and a $51.00 price target on the stock. Citigroup reaffirmed a “buy” rating on shares of Zymeworks in a report on Tuesday, June 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock.